Sign In
Buy PPBT
$1.40
+0.0300 (+2.19%)
At Close: Jul 31, 2026
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
07:00am, Tuesday, 27'th Feb 2024
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEW
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
07:00am, Tuesday, 13'th Feb 2024
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT),
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
07:30am, Thursday, 01'st Feb 2024
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
08:05am, Wednesday, 20'th Dec 2023
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
06:50am, Thursday, 14'th Dec 2023
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "th
Purple Biotech Reports Third Quarter 2023 Financial Results
06:50am, Tuesday, 21'st Nov 2023
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1 /2 Do s e Escalation Study Patients ' E nrollment in the Phase 2 Randomized CM24 Pancreatic Cancer T rial A head of T imelines C
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
03:55pm, Thursday, 19'th Oct 2023
REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
Purple Biotech Announces $5 Million Registered Direct Offering
08:00am, Tuesday, 17'th Oct 2023
REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies t
Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action
07:50am, Friday, 06'th Oct 2023
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
07:50am, Tuesday, 03'rd Oct 2023
REHOVOT, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes
Purple Biotech Reports Second Quarter 2023 Financial Results
09:29am, Tuesday, 22'nd Aug 2023
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway ext
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
08:15am, Tuesday, 11'th Jul 2023
REHOVOT, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harnes
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
07:00am, Tuesday, 18'th Apr 2023
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, e
Purple Biotech to Present at the Jefferies London Healthcare Conference
07:30am, Wednesday, 03'rd Nov 2021
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
07:38am, Wednesday, 26'th May 2021
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl
